Anal cancer has been
repeatedly linked to sexual activity. It appears that, like
cervical disease, risk for anal cancer is increased in women and men
with more lifetime sexual partners. Frish et al conducted a case
control study that revealed that women with greater than 10 lifetime
sexual partners had a 5 fold increase in their risk for anal cancer
when compared to women with one lifetime partner. Intercourse
before the age of 20 with greater than 4 partners increased risk
three fold when compared to women who had not yet had intercourse at
that age. Female cases were also more likely to have had anal
intercourse (odds ratio 2.2) and to have started this behavior
before the age of 30 (odds ration 4.4). 2/3 of female cases had a
history of anogenital warts; anal warts alone increasing the risk
nearly 10 fold (odds ratio 9.8). The odds ratio was also increased
if there was a prior history of STD (odds ratio for gonorrhea of 4.4
and 2.2 for trichomonas). There was also an increased odds ratio in
women with previously diagnosed cervical neoplasia (odds ratio of
2.6)[8].
Men in this same
study showed a similar profile. Interestingly greater than 10
female lifetime sex partners increased the odds ratio to 2.8 when
compares to men with 2-3 lifetime partners. Other STDs, history of
receptive anal intercourse, and anal warts also increased the odds
of being a male case of anal carcinoma. In men who had never
reported having a heterosexual relationship, the odds ratio
increased to 12.7. [8]
It has been
recognized that MSMs are at higher risk for anal cancer even before
the dawn of the AIDS epidemic [2]. The incidence is estimated to
be approaching 35 cases per 100, 000, about the same incidence as
cervical cancer before routine PAP smear screening programs were
created[7]. Homosexual men, regardless of HIV serostatus are more
likely to have ASIL. HIV infection increases the risk that that
ASIL will be of a higher grade and that if LSIL is found that it
will progress to HSIL within two years. Lower CD4 counts also
increased the relative risk of developing HSIL. Other risk factors
for progression of ASIL are presence of more oncogenic strains of
HPV in the anal canal and HPV positive serology [7].
It is as of yet
unclear what impact HAART will have on anal cancer and dysplasia.
Some postulate that dysplasia may be more likely to regress with
increasing CD4 counts. Others predict that these life-extending
meds may lead to more cases of anal cancer as the increasing life
expectancy of HIV infected individuals provides time for dysplasia
to progress to invasive cancer.
Invasive anal
cancer is 6.8 times more common in HIV positive women than their HIV
negative counterparts. HIV positive women are also similarly more
likely to have ASIL than their matched HIV negative counterparts.
In one natural-history cohort study of women with high-risk sexual
behavior, 26% of HIV positive women compared to 8% of HIV negative
women had abnormal anal cytologies. 6% of HIV positive women had
HSIL compared to 2 % among HIV negative women. Abnormal
cervical cytology in HIV positive women also increased the risk of
abnormal anal cytology (2.2 relative risk)[9].
There is a paucity
of information regarding HIV negative women and their ASIL risk
related to their cervical cytology. It is thought, however, that
all women with a history of cervical disease are also at increased
risk for development of anal cancer [8]. In one prospective cohort
study, a history of HPV genital infection increased the relative
risk of development of anal cancer by 8 fold. Though the confidence
interval of this relative risk includes one because the number of
anal cancer cases reported in this cohort were small, there appears
to be an association between cervical disease and anal
dysplasia[10].
Smoking has also been identified as a risk factor for anal cancer
independent of sexual practices [11]. Alcohol consumption is
not cited as a risk factor in the medical literature on anal
cancer.
Another risk factor
appears to be chronic pharmacologic immunosupression. One study
looking at patient with renal allografts revealed a 100-fold
increase in the incidence of anogenital cancers when compared to the
general population [12]. It is unclear if chronic corticosteroids
use for other disease processes is a risk factor for anal cancer
[11].